Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Frequently asked questions
What sector does Emerald Bioscience Inc (SKYE) operate in?
Emerald Bioscience Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Emerald Bioscience Inc (SKYE) current stock price?
As of the latest data, Emerald Bioscience Inc stock price is $0.52, with a previous close of $0.47. Emerald Bioscience Inc gained $0.05 in the last trading session, representing a 10.11% increase.
What is Emerald Bioscience Inc (SKYE) current market capitalization?
Emerald Bioscience Inc market cap is approximately 18.25 million.
What is Emerald Bioscience Inc (SKYE) Earnings Per Share (EPS)?
The trailing EPS is -$1.45, and the forward EPS is -$1.13.
What is Emerald Bioscience Inc (SKYE) EBITDA?
Emerald Bioscience Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -12.33 million.
Does Emerald Bioscience Inc (SKYE) pay dividends?
No. Emerald Bioscience Inc does not pay a dividend.
When is Emerald Bioscience Inc (SKYE) next earnings report?
Emerald Bioscience Inc is expected to release its next earnings report on June 30, 2026.
What is Emerald Bioscience Inc (SKYE) beta (volatility) score?
Emerald Bioscience Inc has a beta of 2.944, indicating very high volatility compared to the market.
